Objective: To evaluate the
efficacy and
safety of
tirofiban infusion to
infarct related vessels on
patients with
ST segment elevation myocardial infarction (
STEMI ) during
emergency percutaneous coronary intervention (PCI).
Methods: From Jan 2013 to Jun 2014, a total of 30
STEMI patients were enrolled as
tirofiban group (
tirofiban 500μg was infused to
infarct related vessels during
emergency PCI), and received
intravenous drip of
tirofiban 0.1 μg•kg-1•min-1 for 24h after
stent implantation; another 31
STEMI patients were regarded as pure stenting group during the same period and they received direct
stent implantation during
emergency PCI.
Computer -assisted Quantitative Blush Evaluator (QuBE) score, left
ventricular ejection fraction (LVEF) during
hospitalization and after six-month follow-up and
incidence rate of major adverse cardiovascular events were compared and analyzed between two groups.
Results: There were no significant difference in baseline data between two groups, P>0.05. Compared with pure stenting group, after six months, there were significant rise in QuBE score [(10.88±5.03) scores vs. (14.70±6.69) scores] and LVEF [(57.19±4.59)% vs. (59.80±5.34)%], and significant reduction in
incidence rate of
MACE (35.5% vs. 10.0%) in
tirofiban group, P<0.05 all.
Conclusion: Tirofiban application in
infarct related vessels during
emergency PCI in
STEMI patients can effectively and safely improve myocardial
microcirculation perfusion level and it is worth extending.